Lyell Immunopharma, Inc. (Lyell), (Nasdaq: LYEL), a T cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors, today announced the pricing of its initial public offering of 25,000,000 shares of its common stock at a public offering price of $17.00 per share. All of the shares of common stock are being offered by Lyell. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Lyell, are expected to be approximately $425 million. Lyell’s common stock is expected to begin trading on the Nasdaq Global Select Market on June 17, 2021 under the ticker symbol “LYEL.” The offering is expected to close on June 21, 2021, subject to the satisfaction of customary closing conditions. In addition, Lyell has granted the underwriters a 30-day option to purchase up to an additional 3,750,000 shares of its common stock at the initial public offering price, less the underwriting discounts and commissions.
Goldman Sachs & Co. LLC, BofA Securities, J.P. Morgan and Morgan Stanley are acting as joint book-running managers for the offering.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.